Editorial|Articles in Press, 103684

Spotlight on the impact of transfusion support, the detrimental influence of blood donation microbiomes on hematological immune-related toxicities, and the sustained efficacy and survival outcomes of immune checkpoint inhibitors’ treated cancer patients

Published:February 28, 2023DOI:
      The main objective of the 2022 issues of the What’s Happening section was to encourage an international team of experts to provide the readers with concise reviews of topics of current interest on strategies for risk assessment, predictive diagnosis, and patient management to bring, today, what will be tomorrow’s news.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      Dr. Jerard Seghatchian, M.D., Ph.D. A former principal scientific advisor in transfusion and apheresis technologies at NHS BTTS. An International Consultancy with expertise in enhancing innovations in modern precision personalized blood component therapies and training in quality audit/inspection and GMP compliance, traceability, safety, and risk reduction strategies. London, England, UK